Blogs & News
Implementing Precision Medicine with the Liver Cancer Collaborative
At the start of the year, I blogged about how we have been working very closely with the Liver Cancer Collaborative (LCC) in Australia, using the DRE as a multi-modal data hub to provide access to clinical, multi-omic and imaging data and crucially, identify cohorts of biosamples for holistic multi-modal analysis.
We continue to expand on this work and have just published a joint paper that goes into detail on the aims of the collaboration, looking to the future of how liver cancer research can be transformed as the platform develops and opens to wider use by adopting the Federated Node and facilitating connectivity between other DRE systems, allowing for truly global collaboration and research.
Liver cancer remains one of the most challenging cancers worldwide, with a high mortality rate due to late diagnosis and limited treatment options. LCC is committed to transforming liver cancer research and treatment through a clinician-led biorepository and an integrated digital research environment (DRE).
The DRE will enable LCC to:
• Integrate clinical, genomic, and research data to facilitate precision medicine.
• Provide a secure platform for data sharing and collaboration.
• Enhance research capabilities through innovative technologies such as multi-omics and patient-derived models.
• Ultimately improve liver cancer treatment outcomes and patient care.
The paper provides insight into the technical platform developed by Aridhia and LCC, with the DRE at its heart, including an integration with the OpenSpecimen platform to provide researchers with the ability to identify and request access to biosamples relevant to their studies.
We are proud to work with LCC and, as the platform develops, are excited about the opportunities that lie ahead to revolutionise care for liver cancer patients.
You can find the complete joint paper here.